<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04081077</url>
  </required_header>
  <id_info>
    <org_study_id>PRACTECAL-PKPD</org_study_id>
    <nct_id>NCT04081077</nct_id>
  </id_info>
  <brief_title>PRACTECAL-PKPD Sub Study</brief_title>
  <acronym>PRACTECAL-PKPD</acronym>
  <official_title>Pharmacokinetics and Pharmacodynamics Sub-study for TB-PRACTECAL Clinical Trial ( PRACTECAL-PKPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medecins Sans Frontieres, Netherlands</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Global Alliance for TB Drug Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Drugs for Neglected Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swiss Tropical &amp; Public Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>eResearch Technology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, Republic of Uzbekistan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, Belarus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>TB &amp; HIV Investigative Network (THINK)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liverpool School of Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical HIV Reserach Unit, Wits Health Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hackensack Meridian Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco (UCSF), USA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine Clinical Reserach Department</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College London Institute for Global Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Minsk Republican Research and Practical Centre for Pulmonology and Tuberculosis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medecins Sans Frontieres, Netherlands</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PRACTECAL-PKPD is an exploratory pharmacokinetic and pharmacodynamic sub-study investigating
      the relationship between the patients' exposure to anti- tuberculosis (TB) drugs in the
      TB-PRACTECAL trial investigational regimens and their respective treatment outcomes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRACTECAL-PKPD is a sub-study of the main TB-PRACTECAL phase II-III trial for the treatment
      of biologically confirmed pulmonary multi drug or extensively drug-resistant TB (M/XDR-TB).
      TB-PRACTECAL is a multicentre, open label, phase 2-3 randomised controlled trial evaluating 6
      months, exclusively oral regimens containing bedaquiline (B), pretomanid (Pa), linezolid
      (Lzd) +/- moxifloxacin (Mfx) or clofazimine (Cfz) for the treatment of microbiologically
      confirmed pulmonary M/XDR-TB.

      Primary objective Measure the plasma concentrations of pretomanid, linezolid, bedaquiline,
      clofazimine and moxifloxacin in a sub-set of patients in the TB-PRACTECAL trial and using
      population pharmacokinetic (PK) models, estimate the population exposure metrics (minimum
      plasma concentration (Cmin), mean plasma concentration (Cmean), maximum plasma concentration
      (Cmax), plasma concentration versus time curve (AUC)) for the individual drugs in the
      TB-PRACTECAL trial.

      Secondary objectives Develop a population pharmacodynamic model to explore the relationship
      between drug exposure, baseline minimum inhibitory concentrations and both
      mycobacteriological and clinical treatment success Develop a population pharmacodynamics
      model and identify PK parameters that are associated with treatment emergent toxicity Explore
      covariates specific to the regimens and study population Use results of above objectives to
      develop a hypothesis on the optimal dosing of linezolid and clofazimine Explore the
      pharmacogenomic factors associated with efficacy and toxicity of the investigational drugs
      Analyse adherence/exposure to the investigational regimen(s) by analysing anti-TB drug levels
      in small hair samples Assess the potential of using hair drug levels to develop safety and
      efficacy pharmacodynamic models Conduct clinical validation of a dried blood quantification
      method using volumetric absorptive microsampling.

      Procedures:

      4 ml (vacutainer tube, lithium heparin) of blood will be collected from the hand, forearm or
      antecubital vein at each sampling occasion and moment for the PK. The sampling occasions are
      on Day 1, Weeks 8, 12, 16, 20, 24, 32 and 72. On Day 1, blood will be collected just before
      drugs intake, then 2 and 23 hours after drugs intake. On week 8, blood will be collected just
      before drugs intake, then 6.5 and 23 hours post dose. At weeks 12, 16, 20 and 24 the blood
      will be collected within 30 minutes before taking the dose. Samples from week 32 and 72 will
      be collected whenever feasible after the patients have completed their treatment so blood
      collection is not relative to drug intake on that occasion. These have been included to
      capture the elimination phases of the drugs which have long terminal half-lives.

      A subgroup of patients will also participate to the clinical validation study of a dried
      blood quantification method using volumetric absorptive microsampling. 2ml of blood and a
      drop of blood from the finger tips will be collected at the following sampling occasions: day
      1, week 8, 12, 16, 20 and 24.

      In the small hair study, a small thatch of hair will be cut as close as possible to the scalp
      from the occiput at weeks 8, 16, 24, 32 and 72.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic: Cmax</measure>
    <time_frame>72 weeks</time_frame>
    <description>Plasma concentrations, their timing in relation to dose intake and start of treatment will be used in a population PK model to estimate Peak Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: AUC</measure>
    <time_frame>72 weeks</time_frame>
    <description>Plasma concentrations, their timing in relation to dose intake and start of treatment will be used in a population PK model to estimate the area under the plasma concentration versus time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: T1/2</measure>
    <time_frame>72 weeks</time_frame>
    <description>Plasma concentrations, their timing in relation to dose intake and start of treatment will be used in a population PK model to estimate the elimnation half life (T1/2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic: Tmax</measure>
    <time_frame>72 weeks</time_frame>
    <description>Plasma concentrations, their timing in relation to dose intake and start of treatment will be used in a population PK model to estimate the time present at maximum plamsa concentration (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>72 weeks</time_frame>
    <description>Number of patients with serious adverse events (SAE), adverse events of special interest (AESI) and other AEs with their respective severity grading.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics: Culture Conversion 24 weeks post treatment [Efficacy]</measure>
    <time_frame>24 weeks</time_frame>
    <description>Percentage of patients with culture conversion in liquid media at 24 weeks post randomisation</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Multi-drug Resistant Tuberculosis</condition>
  <condition>Extensively Drug-Resistant Tuberculosis</condition>
  <condition>Pulmonary Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Regimen 1: Bedaquiline, Pretomanid, Linezolid, Moxifloxacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Moxifloxacin: 400 mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 2:Bedaquiline, Pretomanid, Linezolid, Clofazimine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated Clofazimine: 50 mg (less than 33 kg), 100 mg (more than 33 kg) for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen 3: Bedaquiline, Pretomanid, Linezolid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bedaquiline: 400 mg once daily for 2 weeks followed by 200 mg 3 times per week for 22 weeks Pretomanid: 200mg once daily for 24 weeks Linezolid: 600mg daily for 16 weeks then 300mg daily (or 600mg x3/wk) for the remaining 8 weeks or earlier when moderately tolerated)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bedaquiline</intervention_name>
    <description>Bedaquiline is a diarylquinoline class antimicrobial which blocks the proton pump for ATP synthase of mycobacteria. This in turn blocks the ATP production required for cellular energy production and leading to cell death.</description>
    <arm_group_label>Regimen 1: Bedaquiline, Pretomanid, Linezolid, Moxifloxacin</arm_group_label>
    <arm_group_label>Regimen 2:Bedaquiline, Pretomanid, Linezolid, Clofazimine</arm_group_label>
    <arm_group_label>Regimen 3: Bedaquiline, Pretomanid, Linezolid</arm_group_label>
    <other_name>Sirturo</other_name>
    <other_name>R207910</other_name>
    <other_name>TMC207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pretomanid</intervention_name>
    <description>Pretomanid is an nitroimidazole class antimicrobial which interferes with cell wall biosynthesis in mycobacteria. It may have other mechanisms of action as well in non-replicating mycobacteria.</description>
    <arm_group_label>Regimen 1: Bedaquiline, Pretomanid, Linezolid, Moxifloxacin</arm_group_label>
    <arm_group_label>Regimen 2:Bedaquiline, Pretomanid, Linezolid, Clofazimine</arm_group_label>
    <arm_group_label>Regimen 3: Bedaquiline, Pretomanid, Linezolid</arm_group_label>
    <other_name>PA-824</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Moxifloxacin is an 8-methoxyquinolone class antimicrobial that is a potent inhibitor of DNA gyrase and topoisomerase IV in bacteria</description>
    <arm_group_label>Regimen 1: Bedaquiline, Pretomanid, Linezolid, Moxifloxacin</arm_group_label>
    <other_name>Avelox, BAY 12-8039</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid</intervention_name>
    <description>Linezolid, an oxazolidinone class antimicrobial which works by inhibiting ribosomal protein synthesis. It is approved for Gram-positive bacterial infections, and is increasingly being used for drug resistant TB disease.</description>
    <arm_group_label>Regimen 1: Bedaquiline, Pretomanid, Linezolid, Moxifloxacin</arm_group_label>
    <arm_group_label>Regimen 2:Bedaquiline, Pretomanid, Linezolid, Clofazimine</arm_group_label>
    <arm_group_label>Regimen 3: Bedaquiline, Pretomanid, Linezolid</arm_group_label>
    <other_name>Zyvox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clofazimine</intervention_name>
    <description>Clofazimine (Cfz) is a lipophilic riminophenazine licensed for treatment of leprosy. Its mechanism(s) of action remains unclear, but existing evidence suggests production of reactive oxygen species within Mycobacterium tuberculosis is one mechanism.</description>
    <arm_group_label>Regimen 2:Bedaquiline, Pretomanid, Linezolid, Clofazimine</arm_group_label>
    <other_name>Lamprene</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Patients eligible for inclusion in the trial must fulfil all of the following criteria:

          -  Male or female subjects aged 15 years of age or above, regardless of HIV status;

          -  Microbiological test (molecular or phenotypic) confirming presence of M. tuberculosis;

          -  Resistant to at least rifampicin by either molecular or phenotypic drug susceptibility
             test;

          -  Completed informed consent form (ICF);

        Exclusion criteria:

          -  Known allergies, hypersensitivity, or intolerance to any of the study drugs;

          -  Pregnant or breast-feeding; or unwilling to use appropriate contraceptive measures

          -  Liver enzymes &gt;3 times the upper limit of normal;

          -  Any condition (social or medical) which, in the opinion of the investigator, would
             make study participation unsafe;

          -  Taking any medications contraindicated with the medicines in the trial; QTcF &gt; 450ms;

          -  One or more risk factors for QT prolongation (excluding age and gender) or other
             uncorrected risk factors for TdP;

          -  History of cardiac disease, syncopal episodes, symptomatic or asymptomatic arrhythmias
             (with the exception of sinus arrhythmia);

          -  Any baseline biochemical laboratory value consistent with Grade 4 toxicity.

          -  Moribund

          -  Known resistance to bedaquiline, pretomanid, delamanid or linezolid.

          -  Prior use of bedaquiline and/or pretomanid and/or linezolid and/or delamanid for one
             or more months.

          -  Patients not eligible to start a new course of MDR-TB/XDR-TB treatment according to
             local protocol, including but not limited to:

               -  currently on MDR-TB treatment for more than 2 weeks (and not failing)

               -  unstable address

               -  loss to follow-up in previous treatment with no change in circumstance and
                  motivation.

          -  Tuberculous meningoencephalitis, brain abscesses, osteomyelitis or arthritis.

        PKPD inclusion/exclusion:

          -  Adult patients recruited into the investigational arms of the TB-PRACTECAL trial in
             the approved sites.

          -  Willing to sign the sub-study informed consent form after agreeing to the additional
             blood draws.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bern Nyang'wa, MB BS, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medecins Sans Frontieres, Netherlands</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emma Douch</last_name>
    <phone>+4402074046600</phone>
    <email>emma.douch@london.msf.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Republican Scientific and Practical Centre for Pulmonology and Tuberculosis hospital</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
    <contact>
      <last_name>Animesh Sinha, MD</last_name>
      <phone>+375 297030902</phone>
      <email>minsk-ct-mtl@oca.msf.org</email>
    </contact>
    <investigator>
      <last_name>Varvara Solodovnikova,, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helen Jospeh Hospital</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2041</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Ina de Jongh</last_name>
      <phone>+27 11 276-8803</phone>
      <email>idejongh@witshealth.co.za</email>
    </contact>
    <investigator>
      <last_name>Mohammed Rassool, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helen Joseph Hospital</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2092</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Ina de Jongh</last_name>
      <phone>+27 11 276-8803</phone>
      <email>idejongh@witshealth.co.za</email>
    </contact>
    <investigator>
      <last_name>Mohammed Rassool Rassool, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Doris Goodwin Hospital</name>
      <address>
        <city>Pietermaritzburg</city>
        <state>KwaZulu Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Ronelle M Moodliar</last_name>
      <phone>0333980054</phone>
      <email>R.moodliar@thinksa.org.za</email>
    </contact>
    <investigator>
      <last_name>Ronelle Moodliar, MBBS, MMed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King DinuZulu Hospital</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Ina de Jongh</last_name>
      <phone>+27 11 276-8800</phone>
      <email>idejongh@witshealth.co.za</email>
    </contact>
    <investigator>
      <last_name>Nosipho Ngubane, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King DinuZulu Hospital</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4091</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Ina de Jongh</last_name>
      <phone>+27 11 276-8803</phone>
      <email>idejongh@witshealth.co.za</email>
    </contact>
    <investigator>
      <last_name>Nosipho Ngubane, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Don McKenzie Hospital</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
    <contact>
      <last_name>Ronelle Moodliar</last_name>
      <phone>0333980054</phone>
      <email>R.moodliar@thinksa.org.za</email>
    </contact>
    <investigator>
      <last_name>Ronelle Moodliar, MBBS,MMed</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>South Africa</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 29, 2019</study_first_submitted>
  <study_first_submitted_qc>September 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2019</study_first_posted>
  <last_update_submitted>September 6, 2019</last_update_submitted>
  <last_update_submitted_qc>September 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmcogenomics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Bedaquiline</keyword>
  <keyword>Pretomanid</keyword>
  <keyword>Linezolid</keyword>
  <keyword>Clofazimine</keyword>
  <keyword>Moxifloxacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
    <mesh_term>Extensively Drug-Resistant Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Clofazimine</mesh_term>
    <mesh_term>Bedaquiline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

